Dupilumab Monthly Dose De-Escalation Maintains Efficacy in CRSwNP: A Two-Year Real-World Study. De Corso E, Montuori C, De Maio G, D'Auria LM, et al. Laryngoscope 2025;135:2267-2274.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

De Corso E, Montuori C, De Maio G, D'Auria LM, et al. Dupilumab Monthly Dose De-Escalation Maintains Efficacy in CRSwNP: A Two-Year Real-World Study. Laryngoscope 2025;135:2267-2274.
PMID: 40152155